MC DX4
Alternative Names: MC-DX4Latest Information Update: 07 Oct 2022
At a glance
- Originator miRecule
- Class Antibodies; Antisense oligonucleotides; Drug conjugates; Immunoconjugates
- Mechanism of Action DUX4L1 protein expression inhibitors; Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Facioscapulohumeral muscular dystrophy
Most Recent Events
- 04 Oct 2022 miRecule and Sanofi agree to co-promote and co-develop MC DX4 for Facioscapulohumeral muscular dystrophy
- 07 Jun 2021 Pharmacodynamics data from early research in Facioscapulohumeral muscular dystrophy presented at the 27th Annual FSHD International Research Congress (IRC-2020)
- 02 Jun 2021 miRecule has patent protection for RNA chemistry to develop RNA therapeutics before May 2021 (miRecule website, June 2021)